title: Geniposide ameliorates TNBS-induced experimental colitis in rats via reducing inflammatory cytokine release and restoring impaired intestinal barrier function.
abstract: Geniposide is an iridoid glycosides purified from the fruit of Gardenia jasminoides Ellis, which is known to have antiinflammatory, anti-oxidative and anti-tumor activities. The present study aimed to investigate the effects of geniposide on experimental rat colitis and to reveal the related mechanisms. Experimental rat colitis was induced by rectal administration of a TNBS solution. The rats were treated with geniposide (25, 50 mg·kg-1·d-1, ig) or with sulfasalazine (SASP, 100 mg·kg-1·d-1, ig) as positive control for 14 consecutive days. A Caco-2 cell monolayer exposed to lipopolysaccharides (LPS) was used as an epithelial barrier dysfunction model. Transepithelial electrical resistance (TER) was measured to evaluate intestinal barrier function. In rats with TNBS-induced colitis, administration of geniposide or SASP significantly increased the TNBS-decreased body weight and ameliorated TNBS-induced experimental colitis and related symptoms. Geniposide or SASP suppressed inflammatory cytokine (TNF-α, IL-1β, and IL-6) release and neutrophil infiltration (myeloperoxidase activity) in the colon. In Caco-2 cells, geniposide (25-100 μg/mL) ameliorated LPS-induced endothelial barrier dysfunction via dose-dependently increasing transepithelial electrical resistance (TER). The results from both in vivo and in vitro studies revealed that geniposide down-regulated NF-κB, COX-2, iNOS and MLCK protein expression, up-regulated the expression of tight junction proteins (occludin and ZO-1), and facilitated AMPK phosphorylation. Both AMPK siRNA transfection and AMPK overexpression abrogated the geniposide-reduced MLCK protein expression, suggesting that geniposide ameliorated barrier dysfunction via AMPK-mediated inhibition of the MLCK pathway. In conclusion, geniposide ameliorated TNBS-induced experimental rat colitis by both reducing inflammation and modulating the disrupted epithelial barrier function via activating the AMPK signaling pathway.
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Li
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Xu
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Chang-Chun
authors.initials: CC
authors.lastname: Yu
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Meng-Qiao
authors.initials: MQ
authors.lastname: Lian
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Ze-Yao
authors.initials: ZY
authors.lastname: Tang
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Chuan-Xun
authors.initials: CX
authors.lastname: Li
authors.affiliation: Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lin
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D018938:Caco-2 Cells; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D015536:Down-Regulation; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D039823:Iridoids / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D020556:Neutrophil Infiltration / Q000187:drug effects; D010539:Permeability; D017207:Rats, Sprague-Dawley; D012460:Sulfasalazine / Q000627:therapeutic use; D014302:Trinitrobenzenesulfonic Acid; D015854:Up-Regulation
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D039823:Iridoids; C007835:geniposide; D012460:Sulfasalazine; D014302:Trinitrobenzenesulfonic Acid